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AbstrAct
Objectives To establish prevalence, management and 
long-term outcomes of osteonecrosis (ON) in young people 
diagnosed with acute lymphoblastic leukaemia (ALL) 
between 2003 and 2011.
Design, setting, participants This study assessed 
ON in 3113 patients aged 1–24 years who participated 
in the UK national leukaemia study UKALL 2003. UKALL 
2003 recruited patients in 40 UK hospitals between 2003 
and 2011 and included patients between ages 1 and 25 
diagnosed with ALL.
results 170 patients were diagnosed with ON, giving 
a prevalence of 5.5%. The multivariable analysis showed 
that the risk of ON was highest for children aged between 
10 and 20 years (ages 10–15 years, OR 23.7, 95% CI 14.8 
to 38.0; ages 16–20 years, OR 22.5, 95% CI 12.7 to 39.8, 
compared with age <10 years). Among ethnic groups, 
Asian patients had the highest risk of ON (OR 1.92, 95% CI 
1.1 to 3.6, compared with White patients). Eighty-five per 
cent of patients with ON had multifocal ON. Thirty-eight 
per cent of patients with ON required surgery and 19% of 
patients with ON required a hip replacement. Fifteen per 
cent of patients who had surgery still describe significant 
disability or use of a wheelchair.
conclusions ON has considerable morbidity for patients 
being treated for ALL, with a high burden of surgery. 
Age and ethnicity were found to be the most significant 
risk factors for development of ON, with Asian patients 
and patients aged 10–20 years at diagnosis of ALL at 
greatest risk. These results will help risk stratify patients at 
diagnosis of ALL, and help tailor future prospective studies 
in this area.
IntrODuctIOn
Acute lymphoblastic leukaemia (ALL) is the 
most common type of children’s leukaemia, 
accounting for 78% of all leukaemias diag-
nosed in paediatrics,1 with 420 patients aged 
24 years or younger newly diagnosed each 
year in the UK.2
As progressive intensification of chemo-
therapy continues to improve outcomes,3 4 
there has been an increasing focus on under-
standing and limiting the long-term compli-
cations of treatment for paediatric ALL. The 
challenge is to maintain excellent outcomes 
for patients with ALL while reducing disability.
Morbidity after ALL varies considerably 
with treatment received. Osteonecrosis (ON) 
is one of the most debilitating complications 
seen during or after treatment for ALL, and 
is mostly an iatrogenic complication that has 
been attributed to increased use of gluco-
corticoids.5 Asparaginase,6 high-dose meth-
otrexate7 and cyclophosphamide8 have also 
been implicated; however, causation has 
not been established. Development of ON 
appears to be multifactorial, but is being 
reported more commonly in patients as 
survival improves and high-dose steroids have 
become embedded in treatment regimens.9 10
The National Cancer Institute 
(NCI) Common Terminology Criteria for 
Adverse Events provides an internationally 
recognised definition of ON, and defines 
it as ‘a disorder characterised by necrotic 
changes in the bone tissue due to interrup-
tion of blood supply’.11 The Ponte di Legno 
toxicity working group developed a more 
clinically relevant consensus-based defini-
tion and grading system to enable reliable 
What this study hopes to add?
 ► This study has found a UK prevalence of 
symptomatic ON of 5.5%.
 ► Asian ethnicity is a significant risk factor for 
development of ON.
 ► Analysis highlights the burden of surgery in 
patients, with 38% of patients with ON requiring 
some form of surgery.
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Original article
What is already known on this topic?
 ► Patients being treated for acute lymphoblastic 
leukaemia (ALL) are at increased risk of 
development of osteonecrosis (ON), which is likely 
to be an iatrogenic complication.
 ► Previous studies have found that patients aged over 
10 years at diagnosis of ALL have increased risk of 
developing ON.
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comparison of frequency and severity,12 with ON defined 
as ‘result[ing] from the temporary or permanent loss 
of the blood supply to the bones, which can cause pain, 
limitation in activity of daily living, and potentially the 
collapse of an articulating surface with enhanced pain 
and development of arthritis’.12
There is little published information on long-term 
outcomes for children and young people who develop 
ON subsequent to treatment for ALL, and as such this 
study is crucial in understanding the natural history and 
current management of ON in the UK.
The primary outcome measure of this study was to 
report the UK prevalence of symptomatic ON in young 
people with ALL. Secondary outcome measures included 
identification of risk factors for development of ON, 
timing of development of symptomatic ON, time taken 
to diagnose ON, joints affected by ON, surgical require-
ments and long-term outcomes in patients with ON.
MethODs
study population
A total of 3207 patients aged 1–24 years were registered 
onto the UK ALL trial UKALL 2003, of whom 3113 were 
eligible for analysis, and were included in this study. 
Reasons for exclusion from analysis included 70 patients 
who were Philadelphia chromosome positive, 14 patients 
who were misdiagnosed, 7 patients who withdrew consent 
and 3 patients who were registered twice. Philadelphia 
chromosome-positive patients were excluded as they 
were treated on alternative treatment protocols once 
Philadelphia chromosome status was established.
Patients were recruited into UKALL 2003 in 40 UK 
hospitals between 2003 and 2011.13 All patients had a 
diagnosis of ALL, which was diagnosed with standard 
morphological and flow cytometric criteria.14 Patients 
were categorised into standard, intermediate and high-
risk groups based on a combination of NCI criteria, 
cytogenetics and early response to induction therapy, 
assessed by bone marrow blast counts. Standard and 
intermediate-risk patients were assessed for minimal 
residual disease (MRD), and those classified as MRD low 
risk were randomly assigned to receive one or two courses 
of delayed intensification. Full details of treatment have 
been previously described.13 All patients received a daily 
dose of 6 mg/m2 oral dexamethasone during induction 
and maintenance, with a maximum dose of 10 mg. In 
delayed intensification, all patients received 10 mg/m2 
dexamethasone daily for 2 weeks, on alternate weeks, 
with no cap on dose.
Identification of patients with On
Patients with reported bone toxicity were initially iden-
tified by the Clinical Trials Service Unit (CTSU) for 
UKALL 2003, through return of toxicity reporting or 
serious adverse event (SAE) forms. Toxicity reporting 
forms specifically requested data regarding ON, where it 
was categorised as unacceptable bone toxicity (NCI grade 
4). A SAE was defined as any adverse event that resulted 
in death, was life threatening, required unexpected 
hospitalisation or unexpected prolongation of existing 
hospitalisation, or resulted in persistent or significant 
disability or incapacity.
The treatment centre for each patient was contacted 
and provided with a list of all patients identified at that 
centre. A questionnaire was provided for each patient 
and information was also requested for any additional 
UKALL 2003 patients known to the centre as having ON.
Questionnaires and identified patient lists were distrib-
uted for completion by clinicians and research nurses 
in each treatment centre, who were contacted between 
8 April 2015 and 20 April 2015.
All diagnoses of ON were confirmed by assessment 
of radiological reports produced by local radiologists. 
Long-term effects were defined as the effect of ON on 
the patient at the most recent follow-up consultation.
Statistical analysis was undertaken using univariable and 
multivariable logistic regression analyses to identify signifi-
cant differences in the prevalence of ON according to age 
group at diagnosis (ages <10, 10–15 and 16+ years), sex, 
ethnicity (white, black, Asian, other) and treatment (one 
or two rounds of delayed intensification). Ethnicity was 
assigned based on self-report and categories defined in 
each centre. These variables were selected due to results 
of previous studies which suggested their possibility of 
association with development of ON. ORs and 95% CIs 
were reported as measures of association. All analyses were 
carried out using Stata V.14 (StataCorp, 2015).
results
There was a 90% questionnaire response rate between 
9 April 2015 and 12 December 2015 for the 292 eligible 
patients with bone toxicity identified by the CTSU. Of 
these patients, 170 had radiographically confirmed ON, 
giving a prevalence of ON of 5.5% (170/3113) (figure 1). 
Alternative conditions recorded as bone toxicity included 
diagnoses such as fractures, osteopenia and osteoporosis, 
but details of alternative diagnoses and imaging were 
not collated. Median duration of follow-up for patients 
from time of ALL diagnosis was 70.5 months (range 
24–127 months, IQR 54–86 months).
No explanation was given for the lack of questionnaire 
completion in 26 of the 29 non-responders, and notes 
were not available for three of the patients. Demographic 
details of these 29 patients are provided in table 1. These 
patients were not included in our overall analysis of 
patients, as ON was not able to be confirmed.
timing
The median time for development of symptoms of ON 
after diagnosis of ALL or lymphoblastic lymphoma was 
14 months (IQR 10–19 months). The median time to 
diagnosis of ON was 16 months (IQR 12–22 months) 
after the initial diagnosis of ALL. Date of diagnosis of 
ON was not available for six patients. Of the remaining 
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Figure 1 Questionnaire response flow chart. CTSU, Clinical Trials Service Unit.
Table 1 Demographic details for trial patients and patients with missing data
Patients with confirmed 
osteonecrosis (%)
Patients with no 
questionnaire response (%) All trial patients
Age (years) at diagnosis of ALL
  <10 22 (1.0) 3 (0.1) 2279
  10–15 111 (18.3) 10 (1.6) 607
  16+ 35 (15.4) 16 (7.0) 227
Ethnicity
  White 141 (5.6) 25 (1.0) 2525
  Asian 15 (6.5) 2 (0.9) 74
  Black 3 (4.0) 1 (1.3) 232
  Other 11 (7.2) 1 (0.7) 164
  Unknown/missing 0 0 118
Gender
  Male 96 (5.4) 19 (1.1) 1767
  Female 74 (5.5) 10 (0.7) 1346
ALL, acute lymphoblastic leukaemia.
164 patients, 35 were diagnosed with ON in the first year 
after diagnosis of malignancy (21% of all patients diag-
nosed with ON), 91 were diagnosed during the second 
year (55%) and 25 were diagnosed during the third 
year (15%). Eight patients were diagnosed between 3 
and 5 years after diagnosis of malignancy, and only two 
patients were diagnosed with ON after 5 years. The last 
diagnosis of ON was made at 6.26 years after diagnosis of 
ALL. As such, the cumulative incidence of ON diagnosed 
in all patients with ALL was 1.1% at 1 year, 4.0% at 2 years, 
4.9% after 3 years, 5.1% at 5 years and 5.2% at 7 years. For 
patients over the age of 10 at diagnosis of ALL, the cumu-
lative incidence of ON was 3.3% at 1 year, 12.5% at 2 years, 
15.1% at 3 years, 16% at 5 years and 16.2% at 7 years.
risk factors
Age, ethnicity, gender and one versus two delayed inten-
sification blocks were assessed in terms of their univar-
iable and multivariable association with the risk of ON 
(table 2).
It can be seen that age at diagnosis of ALL was found 
to be a significant risk factor for development of ON. 
All age groups above the age of 10 were at significantly 
higher risk for development of ON, although the highest 
OR (23.73) was for those aged between 10 and 15 years 
compared with those less than 10 years of age. The OR 
reduced to 8.32 for those aged over 20 at diagnosis of 
ALL. Figure 2 illustrates the ages of all patients who 
developed ON.
On multivariable regression analysis Asian ethnicity was 
also found to be independently associated with the devel-
opment of ON, with an OR of 1.92 (95% CI 1.05 to 3.55).
Joints affected
The majority of patients had multifocal ON, with a total 
of 480 joints affected in the 170 patients. Only 15% of 
patients (n=26) had unifocal ON. The most commonly 
affected joints were hips (34%), knees (32%), shoulders 
(14%) and ankles (10%). In the patients under the age 
of 10 years at diagnosis of ALL, 21% had unifocal ON.
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Table 2 Results of univariable and multivariable logistic regression analyses for variables associated with osteonecrosis
Univariable logistic regression Multivariable logistic regression
With 
osteonecrosis
(frequency (%))
Without 
osteonecrosis
(frequency (%)) OR CI p Value OR CI p Value
Age (years)
  <10 22 (1) 2257 (99) 1.00
  10–15 111 (18) 496 (82) 22.96 14.38 to 36.64 <0.001 23.73 14.82 to 38.00 <0.001
  16–20 32 (17) 154 (83) 21.31 12.09 to 37.57 <0.001 22.45 12.66 to 39.81 <0.001
  21+ 3 (7) 38 (93) 8.10 2.32 to 28.22 0.001 8.32 2.38 to 29.12 0.001
Ethnicity
  White 141 (6) 2384 (94) 1.00
  Black 3 (4) 71 (96) 0.73 0.23 to 2.35 0.60 0.94 0.27 to 3.23 0.92
  Asian 15 (6) 217 (94) 1.20 0.69 to 2.07 0.53 1.92 1.05 to 3.55 0.04
  Other/
unknown
11 (4) 271 (96) 0.91 0.52 to 1.59 0.73 0.99 0.52 to 1.88 0.99
  Gender
  Male 96 (5) 1671 (95) 0.91 0.65 to 1.28 0.59
  Female 74 (5) 1272 (95) 1.04 0.76 to 1.43 0.79 1.00
Number of delayed intensifications
  2 138 (6) 2142 (94) 1.00
  1 31 (4) 802 (96) 0.85 0.59 to 1.22 0.38 0.99 0.67 to 1.45 0.94
Figure 2 Age of all patients with osteonecrosis.
surgical requirements
Surgery was reported in 65 of the 170 patients (38%), 
with 99 surgical procedures reported in these patients. 
Table 3 shows the types of surgery performed. Hip 
replacements were the most common form of surgery 
required, with 19% of patients affected.
Of the patients for whom arthroscopy was performed, 
three received arthroscopy alone. Additional procedures 
done alongside arthroscopy included synovial debride-
ment, meniscotomy, correction of osteochondral defects, 
reshaping of femoral head, core decompression, removal 
of loose bodies and joint stabilisation.
Sixteen patients (9%) had more than one joint to be 
replaced as a result of ON. Twelve patients had bilat-
eral hip replacements, one patient needed bilateral hip 
replacements and a knee replacement, two needed a 
shoulder and hip replacement, and one had a knee and 
hip replaced.
Of the patients who were under the age of 10 at diag-
nosis of ALL, only four had ON which had any surgical 
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Table 3 Surgical procedures in patients with ON
Type of surgery
Number of 
patients
Percentage of 
patients with ON 
affected
Hip replacement 33 19
Core decompression 22 13
Knee replacement 2 1
Shoulder replacement 2 1
Arthroscopy 10 6
Hip fixation 2 1
Other 10 6
ON, osteonecrosis.
management. Two of these patients needed joint replace-
ments, with the other two receiving core decompression. 
These patients were aged between 6 and 8 at diagnosis 
of ALL.
Despite the high surgical requirement in patients with 
ON, at time of data collection the majority of patients 
who had ON were reported to have either no long-term 
effects (39%, n=66) or minimal disability (38%, n=64). 
Nine per cent of patients continued to have significant 
disability (n=16) and five patients required a wheelchair 
(3%). Six per cent of patients had died and informa-
tion was not available for nine other patients (5%). This 
distribution was similar for patients both over and under 
10 years at diagnosis of ALL.
Of the patients who had surgery, 54% (n=35) were 
reported to have minimal disability and 29% reported 
no long-term effects. Despite surgical intervention, seven 
patients (11%) still described the presence of significant 
disability and three patients required a wheelchair at the 
time of data collection.
DIscussIOn
This is the largest study reporting symptomatic ON in 
childhood ALL, providing long-term follow-up data of 
patients. The prevalence of ON in our population was 
5.5%, and as with previous studies, age was the most 
important risk factor for development of ON.10 15–18 
This study found 18% and 17% of patients between 
10 and 15 years and 16 and 20 years, respectively, develop 
ON, compared with only 1% of patients aged less than 
10 years. It is also noteworthy that there was a significant 
reduction in percentage of patients who developed ON 
if they were diagnosed with ALL after the age of 20, with 
only 7% of this group of patients developing ON. Our 
study is also the first study to describe an increased risk 
of ON in Asian patients after adjustment for age, gender 
and treatment.
Hips, knees, shoulders and ankle joints were most 
commonly affected by ON, and one of the most remark-
able findings was the huge burden of surgery in this 
patient population. Hip replacement was required by 
19% of patients affected by ON, and of all patients over 
10 years of age at diagnosis of ALL, 3.6% required at least 
one joint to be replaced.
Strengths of this work include the large sample size, 
national data set, high response rate and long follow-up 
period.
Limitations include the retrospective nature of the 
study, collecting data from patients from UKALL 2003, 
who were diagnosed with ALL between 1 October 2003 
and 30 August 2011. This may have resulted in recall 
bias, with more severe forms of ON recorded or recalled, 
which could enrich our data with a higher percentage 
of adverse outcomes, such as surgical requirements. 
Asymptomatic ON was not detected, and there was no 
specified threshold for imaging of patients or criteria for 
joint imaging. We were also unable to centrally review the 
MRI images, relying on local reports to determine the 
diagnosis of ON. This study did not incorporate grading 
and severity of ON due to variability in MRI reporting 
across centres. As treatment decisions for each patient 
were made individually, and data on ON severity are not 
available, comparability and generalisability of data on 
management and long-term outcome are limited. The 
reader should also be aware that the patients were treated 
on a specific ALL protocol, outlined previously, and the 
demography of our patients may differ from those in 
other geographical locations.
The prevalence of ON in the literature is strikingly vari-
able from 0.43% to 26.6%.15 19 This variation is likely to 
be due to a number of factors, including study design, 
method of diagnosis of ON and reporting methods. The 
majority of studies also reported only symptomatic ON, 
with much higher rates reported in studies prospectively 
assessing asymptomatic ON.20
In our study, sex of the patient was not found to be a 
significant risk factor for development of ON. Previous 
studies have found conflicting results. A number of 
studies have found female sex to be a risk factor,10 16 18 21–25 
while many others found no such association,17 26–33 even 
when similar treatment regimens were used.10 17 Even 
in groups with the highest reported rates of ON there 
were disparate results—a Children’s Cancer Group study 
reported the disorder more frequently in women,18 while 
no gender differences were found in the Dana-Farber 
Cancer Institute consortium31 and studies at St Jude Chil-
dren’s Research Hospital.30
This study describes the increased prevalence of ON in 
patients of Asian origin. Categorisation of ethnicity poses 
many difficulties,34 as ethnic identification is often subjec-
tive,35 and in this study the method of determining ethnicity 
was not clearly defined. There is also likely to have incon-
sistency between ethnic classifications among different 
countries, particularly with the term ‘Asian’, which in the 
UK is typically used for people who describe themselves as 
South Asian. Studies based in the USA typically used the 
term Asian for those of East Asian origin (Han Chinese 
and Japanese ancestries), in whom there was found to be 
no increased risk of ON.16 There are clear reasons why 
there may be a difference between ethnic groups due to 
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genetic predispositions to obesity, diabetes, variation in 
bone mineralisation and handling of steroids, but more 
needs to be understood about the pathophysiology of ON 
development. In previous studies, white race was found to 
be a risk factor for development of ON,16 18 19 but this is 
not consistently replicated.20 32 In the majority of studies, 
method of assigning ethnicity was typically not discussed, 
and the racial groupings used varied. A number of studies 
separated patients into white and non-white, while others 
included black and Hispanic ethnic groups. No other 
studies specifically commented on South Asian patients, 
and most studies where race was commented upon were 
composed of predominantly white patients.
The median time for development of symptoms of ON 
after diagnosis of ALL was 14 months. We found that 
the number of courses of delayed intensification had no 
impact on the development of ON, despite the increased 
dexamethasone received by patients who received two 
courses of delayed intensification. This suggests the 
initial insult occurs early in the treatment course, with 
symptoms occurring later. This is supported by the 
largest prospective study to date looking at symptomatic 
and asymptomatic ON, where 364 patients with newly 
diagnosed ALL had MRI of the hips and knees after the 
completion of reinduction I (weeks 7–9) and reinduction 
II (weeks 17–19), and at the completion of therapy.20 At 
the first MRI screen, 141 patients were found to have 
asymptomatic ON and 8 patients were found to have 
symptomatic ON. Patients who initially had asymptom-
atic ON were more likely to develop symptomatic ON 
(26%), compared with patients who were initially nega-
tive for ON (14%).
The need for a well-designed prospective study looking 
at ON in young people in the UK with ALL is clear, as the 
natural history of ON in the paediatric population and 
factors predicting long-term outcome are not well defined. 
It is possible that early intervention, prior to development 
of symptoms of ON, would improve joint outcome.
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